World Drug Discovery and Development: Cardio3 BioSciences SA – Product Pipeline Review – H2 2011

• Publication date: December 2011

The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Industries Direct’s proprietary databases, Cardio3 BioSciences SA’s corporate website, SEC filings, investor presentations and featured press releases, both from Cardio3 BioSciences SA and market -specific third party sour...

The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Industries Direct’s proprietary databases, Cardio3 BioSciences SA’s corporate website, SEC filings, investor presentations and featured press releases, both from Cardio3 BioSciences SA and market -specific third party sources, put together by Global Industries Direct’s team.

Scope of the Research

- Cardio3 BioSciences SA - Brief Cardio3 BioSciences SA overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Cardio3 BioSciences SA human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Cardio3 BioSciences SA with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Cardio3 BioSciences SA’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Evaluate Cardio3 BioSciences SA’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Cardio3 BioSciences SA in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Cardio3 BioSciences SA’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Cardio3 BioSciences SA.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Cardio3 BioSciences SA and identify potential opportunities in those areas.

Global Drug Discovery And Development Industry

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Cardio3 BioSciences SA Snapshot 5
Cardio3 BioSciences SA Overview 5
Key Information 5
Key Facts 5
Cardio3 BioSciences SA – Research and Development Overview 6
Key Therapeutic Areas 6
Cardio3 BioSciences SA – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products – Monotherapy 9
Cardio3 BioSciences SA – Pipeline Products Glance 10
Cardio3 BioSciences SA – Late Stage Pipeline 10
Phase III Products/Combination Treatment Modalities 10
Cardio3 BioSciences SA – Early Stage Pipeline Products 11
Pre-Clinical Products/Combination Treatment Modalities 11
Discovery Products/Combination Treatment Modalities 12
Cardio3 BioSciences SA – Drug Profiles 13
Allo-Cure 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
C-Cure 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
C-Cure² 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
C3BS-GQR-1 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
C3BS-GQR-2 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
G-Cure 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Cardio3 BioSciences SA – Pipeline Analysis 19
Cardio3 BioSciences SA – Pipeline Products by Therapeutic Class 19
Cardio3 BioSciences SA – Pipeline Products by Route of Administration 20
Cardio3 BioSciences SA – Pipeline Products by Molecule Type 21
Cardio3 BioSciences SA – Recent Pipeline Updates 22
Cardio3 BioSciences SA – Locations And Subsidiaries 23
Head Office 23
Company's Recent Developments 24
Cardio3 BioSciences SA, Recent Developments 24
June 29, 2010: Cardio3 BioSciences Reports Positive Three-Month Data From Clinical Trial Of C-Cure In Heart Failure 24
December 20, 2010: Cardio3 BioSciences Reports Positive Preclinical Results Of C3BS-GQR-1 In Acute Myocardial Infarction 24
January 19, 2009: Cardio3 BioSciences Receives A US$ 9.4 Mln Investment For Its Lead Product C-Cure 25
November 18, 2008: Cardio3 BioSciences Receives Its Accreditation Number From The Belgian Federal Agency For Medicines And Health Products For The Manufacture Of C-Cure For Human Use 26
November 18, 2008: Cardio3 BioSciences SA Signs A Co-Development Agreement With Artelis SA For The Industrialization Of The Manufacturing Process Of C-Cure And Inaugurate Its New Premises In Mont-Saint-Guibert 27
November 17, 2010: Cardio3 BioSciences Announces Positive Outcome Of C-Cure Phase II Clinical Trial In Heart Failure Patients 28
December 16, 2009: Enrollment Completed In First Stage Of Heart Failure Stem Cell Trial 29
October 16, 2009: Serbian Center Treats First Patient With Heart Failure Stem Cell Therapy 29
August 16, 2010: Cardio3 BioSciences Publishes Science Basis For C-Cure In JACC 30
April 05, 2011: Cardio3 BioSciences Announces Results Of C-Cure Phase II Clinical Trial At 60th Annual American College Of Cardiology Meeting 31
March 02, 2008: Cardio3 BioSciences Treats Its First Patient With C-Cure, A Second-Generation Stem Cell Derived Therapy For Heart Failure 32
Financial Deals Landscape 34
Cardio3 BioSciences SA, Deals Summary 34
Cardio3 BioSciences SA, Pharmaceuticals & Healthcare, Deal Details 35
Venture Financing 35
Cardio3 BioSciences Secures US$ 9.56 Mln In Series B Financing 35
Licensing Agreements 37
Cardio3 BioSciences Enters Into Licensing Agreement With o Clinic 37
Acquisition 38
Grifols Takes Over Minority Stake In Cardio3 BioSciences 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 40
Expert Panel Validation 40
Contact Us 40
Disclaimer 40

List of Tables

Cardio3 BioSciences SA, Facts and Figures 5
Cardio3 BioSciences SA, Key Facts 5
Cardio3 BioSciences SA – Pipeline by Therapy Area and Indication, H2 2011 7
Cardio3 BioSciences SA – Pipeline by Stage of Development, H2 2011 8
Cardio3 BioSciences SA – Monotherapy Products in Pipeline, H2 2011 9
Cardio3 BioSciences SA – Phase III, H2 2011 10
Cardio3 BioSciences SA – Pre-Clinical, H2 2011 11
Cardio3 BioSciences SA – Discovery, H2 2011 12
Cardio3 BioSciences SA - Pipeline By Therapeutic Class, H2 2011 19
Cardio3 BioSciences SA – Pipeline By Route of Administration, H2 2011 20
Cardio3 BioSciences SA – Pipeline By Molecule Type, H2 2011 21
Cardio3 BioSciences SA – Recent Pipeline Updates, H2 2011 22
Cardio3 BioSciences SA, Deals Summary 34
Cardio3 BioSciences Secures US$ 9.56 Mln In Series B Financing 35
Cardio3 BioSciences Enters Into Licensing Agreement With o Clinic 37
Grifols Takes Over Minority Stake In Cardio3 BioSciences 38

List of Figures

Cardio3 BioSciences SA – Pipeline by Therapy Area and Indication, H2 2011 7
Cardio3 BioSciences SA – Pipeline by Stage of Development, H2 2011 8
Cardio3 BioSciences SA – Monotherapy Products in Pipeline, H2 2011 9
Cardio3 BioSciences SA – Pipeline By Route of Administration, H2 2011 20
Cardio3 BioSciences SA – Pipeline By Molecule Type, H2 2011 21